Received Jan 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 5S723 | — |
inappropriate dose of vaccine administered; Inappropriate preparation of medication; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate dose of vaccine administered in a adolescent male patient who received Men ABCWY NVS (Penmenvy) (batch number 5S723, expiry date 08-OCT-2026) for prophylaxis. On 05-JAN-2026, the patient received the 1st dose of Penmenvy. On 05-JAN-2026, an unknown time after receiving Penmenvy, the patient experienced inappropriate dose of vaccine administered (Verbatim: inappropriate dose of vaccine administered) and inappropriate preparation of medication (Verbatim: Inappropriate preparation of medication). The outcome of the inappropriate dose of vaccine administered and inappropriate preparation of medication were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 06-JAN-2026 Nurse called to reported that a patient had been administered only the liquid portion (Men-B) of Penmenvy and to request guidance on how to proceed. She and the reporter discussed SRLs 14169 and 5368. Because GlaxoSmithKline did not make any recommendation, an advisory from the CDC was suggested. The healthcare professional was satisfied with the information and had no further requests. The batch number was provided upon follow up with the reporter.